CTS embraces a company-wide operational excellence initiative designed to change the culture to enhance operations and the service CTS provides to its healthcare partners. As a result of this initiative, CTS teams significantly improved performance in reporting test results on time and increased efficiency by over 10 percent.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...